Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969211 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
A Phase 1 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04969211 is a Phase 1 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT04969211, a Phase 1 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
Interventions
- DRUG VHX-896 and iloperidone
- DRUG Iloperidone and VHX-896
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2021-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969211
The ClinicalTrials.gov registry entry for NCT04969211 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VHX-896 and iloperidone is the first listed.
NCT04969211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04969211 about?
NCT04969211 is a clinical study titled "Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers". This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
What is the current status of trial NCT04969211?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-06-30. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT04969211?
The interventions under investigation include: VHX-896 and iloperidone (DRUG), Iloperidone and VHX-896 (DRUG).
Who is sponsoring clinical trial NCT04969211?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.